targeted gene panel sequencing (TGPS) using cancer specific panels. The pathogenicity potential and actionability of mutations detected on WES was assessed.
Results: Among 420 patients enrolled between December 2011 and December 2013, 283 (67%) patients were analysed for both TGPS and aCGH. The tumour sample of 25 (8.8%) of them presented a flat (or low-dynamic) aCGH profile and no pathogenic mutation on TGPS. We selected the first eligible 10 samples-corresponding to a heterogeneous cohort of different tumour types-to perform WES. This allowed identifying eight mutations of interest in two patients: FGFR3, PDGFRB, and CREBBP missense single-nucleotide variants (SNVs) in an urothelial carcinoma; FGFR2, FBXW7, TP53, and MLH1 missense SNVs as well as an ATM frameshift mutation in a squamous cell carcinoma of the tongue. The FGFR3 alteration had been previously described as an actionable activating mutation and might have resulted in treatment by an FGFR inhibitor. CREBBP and ATM alterations might also have suggested a therapeutic orientation towards epigenetic modifiers and ataxia-telangectasia and Rad3-related inhibitors, respectively.
Conclusion:
The therapeutic added value of performing WES on tumour samples that do not harbour any genetic abnormality on TGPS and aCGH might be limited and variable according to the histotype. Alternative techniques, including RNASeq and methylome analysis, might be more informative in selected cases. Key words: targeted gene panel sequencing, array comparative genomic hybridization, flat profile, whole exome sequencing, precision medicine introduction Over the last 15 years, molecular tumour profiling and precision medicine have allowed tremendous improvements in cancer biology understanding as well as in patients' treatment [1] [2] [3] [4] [5] . Numerous technologies are now available to analyse the tumour's molecular characteristics at the DNA, RNA, or protein level, and the vast majority of oncogenic alterations can currently be identified by using such techniques [6, 7] .
Genomic instability and genetic mutations are the most commonly described mechanisms for leading to cancer development [8, 9] . Therefore, in most cases, the identification of genetic abnormalities provides not only a rationale explanation for cancer development, but also a potential therapeutic opportunity for customizing treatment through the specific targeting of the alteration of interest. However, in some interesting cases, no molecular alteration can be evidenced, thus raising the question of the causal event leading to cancer development [9, 10] .
As not all molecular profiling technologies can be performed on a single tumour sample (for obvious reasons including tumour availability, costs, and platform accessibility), it is crucial to best combine relevant techniques to optimize the likelihood of identifying an actionable alteration of therapeutic interest, and avoid useless and costly explorations [11] . In this context, we investigated the added value of performing whole exome sequencing (WES) on 10 selected eligible tumour samples from heterogeneous histotypes, which did not harbour any genetic alteration after targeted gene panel sequencing (TGPS) and array comparative genomic hybridization (aCGH). This analysis sheds light on the potential for deep WES to evidence additional genetic alterations of therapeutic interest when compared with the association TGPS and aCGH, assessing the relevance of such technique in this context.
materials and methods

MOSCATO-01 trial
Selected patients were included in the MOSCATO-01 trial (MOlecular Screening for CAncer Treatment Optimisation). This trial collected onpurpose tumour samples (from the primary or from a metastatic site) that are immediately fresh-frozen, and subsequently analysed for TGPS and aCGH, in order to screen for actionable alterations. Tumour cellularity was assessed by a senior pathologist on a haematoxylin and eosin slide from the same biopsy core as the one further analysed by aCGH and next-generation sequencing (NGS). Only samples presenting more than 30% of tumour cells were further considered.
targeted gene panel sequencing and comparative genomic hybridization Molecular analysis using TGPS and aCGH was carried out as previously described [12] . Briefly, tumour DNA and germline DNA (whole blood samples) were extracted using DNeasy tissue kit and Qiamp kit respectively (Qiagen, Hilden Germany) according to manufacturer's instructions. TGPS was performed using Ion torrent approach (Ion Torrent PGM, Life Technologies®) with Ion AmpliSeq™ Cancer Panel Primer Pool (CP1) or Ion AmpliSeq™ Cancer Hotspot Panel v2 (CHP2) (Lifetechnologie, Darmstadt, Germany, see www.ampliseq.com). aCGH analysis was performed using SurePrint G3 Human aCGH Microarray 4 × 180 K (Agilent technologies, PaloAlto, CA).
whole exome sequencing
Ten tumour samples without targetable molecular abnormalities on TGPS and a flat aCGH profile were selected for further WES. Two samples per patient (normal and tumour DNA) were analysed. Whole exome was captured from 600 ng of DNA, using Agilent SureSelect v4 Target Enrichment Kit (Human all exome 50 Mb). Sequencing of subsequent library was performed using Illumina HiSeq 2500 in 100 bp paired-end mode in 3 rapid runs (2 lanes per run), outputing more than 1500 M reads per sample. Subsequent FASTQ files were then merged by sample. To improve read quality, adapter sequences were removed using Trimmomatic (v0.32), using authors' recommended parameters [13] . Trimmed reads were mapped using BWA (v0.7.10) with the MEM algorithm option [14] against reference genome hg19, generating a BAM file per sample, which was subsequently sorted, and indexed. Reads known as 'PCR duplicates' were removed using PicardTools (v1.119). BAM files underwent local realignment around InDels and base recalibration following GATK's best practices. Variant calling was performed on processed BAM files using two different variant callers: muTect (v1.1.4) [15] , with default parameters-in order to call somatic SNVs-and GATK [17] , and dbNSFP (V2.1) [18, 19] , using SnpSift (v4.0E) [20] . Variant effects on the genome were inferred using SnpEff (v4.0E) [21] . Variants were then subsequently filtered on the basis of their genomic effect: only missense, non-sense, frameshifts, start/stop codon gain or loss, in-frame InDels and splice site variants were kept. We then applied biological thresholds on the variants in order to retain clinically relevant ones. Were kept all variants that matched the following criteria: allelic frequency ≥10%, tumour read count ≥5 reads, coverage in tumour sample ≥10 reads, frequency in 1000 Genome Project [22] and Exome Sequencing Project (data included in dbNSFP) ≤0.1% [23] . The targetable genes were defined on the basis of the TARGETv2 list of actionable molecular abnormalities (TARGET_db_v2_05042014.xlsx) published by Van Allen et al. [24] . Cellularity and absolute copy number was computed using Sequenza (v2.1.1) [25] following authors' guidelines. When Sequenza analysis resulted in several possibilities, the most plausible one was chosen based on aCGH data and the pathologists review. 
results
Patients' selection
Between December 2011 and December 2013, 420 heavily pretreated patients were included in the MOSCATO-01 trial (supplementary Figure S1 , available at Annals of Oncology online). Among these, tumour biopsy was eventually feasible and performed in 368 patients (87%). aCGH and NGS profiles were assessed in 284 (77%) and 315 (85%) of biopsied patients, respectively, with 283 patients (76%) being profiled for both aCGH and NGS ( Figure 1 ). The median time for delivering results was 20 days.
In order to be eligible for complementary WES, patients' tumour profiles had to meet the following eligibility criteria: (i) presence of at least 30% of tumour cells on the analysed sample; (ii) absence of pathogenic mutation detected by TGPS, and (iii) low-dynamic aCGH profile, as defined by a completely flat profile, a quasi-flat profile or a profile presenting whole chromosome gains or losses that did not correspond to any actionable alteration.
Actionable molecular aberrations were found in 161 (44%) patients among the 316 patients that underwent NGS and/or aCGH. These were subsequently excluded from our analysis. Among the 283 patients that were profiled for both aCGH and NGS, 25 (8.8%) patients presented a flat (or very low dynamic) aCGH profile with no targetable alteration, and no pathogenic mutation by TGPS. Ten of these patients were randomly selected for further WES.
Patients' and tumours' characteristics
Eligible patients presented a variety of tumour types including head and neck tumours (n = 4), urothelial carcinoma (n = 1), mesothelioma (n = 1), thymoma (n = 1), cholangiocarcinoma (n = 1), synovialosarcoma (n = 1), and renal clear-cell carcinoma (n = 1). All patients were heavily pre-treated ( Table 1 ). The biopsied site was the primary lesion for five patients, and a distant metastasis in the remaining five cases (three lung metastases, one pleural metastasis, one sub-cutaneous nodule).
comparative genomic hybridization Among the 10 selected cases, four tumours presented a totally flat aCGH profile, five tumours displayed a quasi-flat aCGH profile and one tumour harboured whole chromosomal abnormalities that were not associated with targetable lesions (Figure 2 ). All samples displayed a very low dynamic aCGH profile, which starkly contrasted with the majority of the biopsied tumours, which displayed very dynamic or informative profiles-targetable copy number alterations, deletions or amplifications were found by aCGH in 76% of the analysed tumours.
targeted gene panel sequencing
Targeted gene panel analysis covered main hot-spot position in 46 and 50 cancer related genes (for CP1 and CHP2, respectively). Treatment lines that were received by the patient before and after the biopsy are described, as these could have caused some increased genomic instability or mutational load (for cytotoxic agents), or specific secondary acquired resistance mutations or amplifications (for targeted therapies). None of the patients presented any outstanding or unexpected response to therapy that would have deserved dedicated investigations. Various head and neck tumours are regrouped (under head and neck in italics) in order to best match the text, although these are of different histologic subtypes and localizations. All those SNVs detected corresponded to synonymous variants, with no consequence on the protein sequence, or polymorphisms with a frequency over 1% in the 1000Genomes [9] and/or ESP [23] databases.
whole exome sequencing
The selected 10 tumour samples were whole exome sequenced using Illumina Hiseq platform at Sanofi-Aventis. Likely pathogenic mutations were selected and pairwise comparisons against TGPS were performed. Among the 10 tumour and matched normal DNA pairs, the coverage depth varied from 70× to 170×; more than 90% of the sequences were covered at a depth of at least 20×. After filtering based on their genomic effect, a total of 607 non-synonymous somatic SNVs were identified by MuTect, corresponding to a median number of 31 coding alterations per tumour sample. WES analysis with HaplotypeCaller also evidenced 1274 InDels (median = 111, range 88-321), including 331 frameshift variants (median = 23; range 18-125) ( Table 2) .
Interestingly, 13 SNVs corresponded to putative mutations of targetable genes, as defined by the Targetv2 list from Van Allen et al. [24] (Table 3) . Five of these alterations were filtered out as non-clinically relevant as they failed to meet the allelic frequency or sufficient depth criteria for our pre-defined filtering (see Materials and Methods). After similar filtering, 12 InDels were identified that were targetable and met sufficient filtering quality. However, 11 of them were removed following manual curation, as these were likely mapping or variant calling errors. Overall, we evidenced seven SNVs and one frameshift mutation of interest involving two tumour samples (Figure 2 ; Table 3 ).
The urothelial carcinoma sample presented FGFR3 (vaf = 0.14), PDGFRB (vaf = 0.13), and CREBBP (vaf = 0.15) missense mutations. The FGFR3 mutation had been previously described in cell lines and bladder samples [26] , and corresponded to a gain of function activating mutation [27] . The PDGFRB mutation had not been previously described; its consequences were deemed to be probably damaging by Polyphen and SIFT. Also, mutations of the epigenetic writer CREBBP have previously been described in 13% of urothelial carcinomas [28, 29] . Analysis of the squamous cell carcinoma (SCC) of the tongue sample revealed one FBXW7 (vaf = 0.13), one FGFR2 (vaf = 0.14) and one MLH1 (vaf = 0.22) missense mutations. None of these variants had previously been described in COSMIC or dbSNP; all deemed to be damaging by Polyphen and SIFT. A deleterious ATM frameshift mutation was also identified.
Of note, two of these seven alterations were included in the CP1/CHP2 panels but had not initially been detected. This might be related to the low allelic frequencies and the localization of the mutation (<10 bp away from the extremity of the CP1/CHP2 amplicon).
tumour cellularity sanity checks
Considering the absence of mutations detected on TGPS, WES, and the flat CGH profile of most of the selected samples, we hypothesized that the first cellularity estimate-although Summary of the single-nucleotide variants (SNVs) that were detected in genes belonging to the TARGETv2 list. Variants emphasized in shaded area were SNVs corresponding to potentially pathogenic alterations, with a variant allele frequency >0.1 and pathogenic non-synonymous alteration. Variants depicted in grey are SNVs located in genes belonging to the TARGETv2 list, but detected at a low and non-significant frequency (0.01-0.1) AA, AMINOACID; altDe, altered allele depth; dbSNP, dbSNP database reference [18, 19] ; refDe, reference allele depth; vaf, variant allele frequency. performed by an experimented senior pathologist-could have been subject to bias and that tumour cellularity was in reality below 30%. In that case, we would have mostly sequenced normal cells, which would have obviously explained the absence of detected genetic abnormalities. In order to confirm an adequate tumour cellularity, two independent sanity checks were performed: first, samples were independently and blindly reviewed by a second senior pathologist, and second, tumour cellularity was inferred from WES data by using a dedicated software (Sequenza [25] ). Results of this sanity check (Table 4) revealed that the samples tumour cellularity was above 30% in all cases according to the second pathologist review, and in 7 of 10 samples according to Sequenza-the median tumour cellularity of the three remaining samples being above 25% [supplementary Figure S2 , available at Annals of Oncology online for confidence interval (CI)]. The median sample tumour cellularity was 60% (30%-90%) according to the first senior pathologist's review-used for sample selection, 50% (30%-90%) according to the second senior pathologist's review, and 33% (25%-98%) according to Sequenza. Discrepancies were noted between the pathological and bioinformatics evaluation, although H&E slides and DNA used for genomic analyses arose from the same core.
discussion
Comprehensive tumour molecular profiling has been the backbone of precision medicine over the last few years, and multiple molecular screening technologies are hopefully becoming more widely available at decreasing costs. However, the optimal sequence, hierarchy of their utilization, and the relative added value of each technology still warrants further investigation [11] . The choice of the molecular profiling technique is currently often driven by its availability. Here, we report the added value of WES on 10 tumour samples that did not present any alteration on TGPS and aCGH. WES allowed identifying eight potentially pathogenic mutations were detected at low allele frequencies in two samples. To our knowledge, this is the first study assessing the added value of WES for patients presenting no detectable alteration on TGPS and aCGH. This population represented less than 10% of the patients included in the MOSCATO-01 trial, suggesting that the combination of both above-cited techniques may ensure the detection of most common alterations [30] . Although those samples are representative of what is realistically obtained in clinical practice when applying these selection criteria, they still represent a small fraction of the overall histologies. Multiple previous studies, notably arising from The Cancer Genome Atlas project, have reported a huge variability of the mutation prevalence among tumour types [6, 31, 32] . Conventional cytotoxic agents can also be mutagenic [33, 34] . Therefore, it is possible that the added value of exome sequencing would differ according to the histotype and to previous treatments. Tumours analysed here were not limited to the ones harbouring the lowest mutation prevalence [6, 32, 35] , and came from heavily pre-treated patients. One can also hypothesize that tumour types represented were oligo-clonal, and only presented subclonal mutations present at low allele frequencies. However, considering the limited size of this cohort, extreme caution is required and no pan-cancer rule can be inferred from the current data.
The discrepancies observed between the pathological and bioinformatics evaluation of tumour cellularity emphasizes the challenges of reliably evaluating the tumour content of core biopsies, and the need for using several complementary techniques. Overall, pathological evaluations were more concordant between them than with bioinformatics analysis. Interestingly, no consistent pattern could be observed between the discrepancies, with pathological evaluation resulting in sometimes higher and sometimes lower values than the bioinformatics evaluation. Intra-biopsy tumour heterogeneity or technical issues (including DNA degradation, contamination, limited reliability of the Sequenza software for low cellularity samples, etc.) might explain these discrepancies. Also, Sequenza sometimes outputted results with a very broad CI, emphasizing the need for caution in results interpretation. Altogether, we have reasonable arguments supporting that tumour cellularity of our samples was adequate and that our findings are not an artefact of technical nature-related for example to the absence of tumour DNA in the analysed sample. However, caution should be applied and revalidation in larger cohorts is warranted.
The fact that potentially targetable mutations were detected in only 2 out of 10 cases suggests that the additional value of performing deep WES is limited, at least for this series. This is not surprising, when considering that most histologies are characterized by a few well-known driver hot-spot mutations that are detected, altogether, in ∼50% of tumours, and by numerous rare or private mutations occurring at very low frequencies (1%-5%) [36, 37] . Targeted gene panels cannot include all mutations, and have focused so far on the most frequent or most actionable targets, including surface receptors, intra-cellular kinases or mediators, and DNA repair genes. Interestingly, one potentially targetable mutation identified by WES was located in the CREBBP gene, coding for an epigenetic modifier. As epigenetic therapies are evolving rapidly now and with promising results even in solid In order to exclude a false-negative result (absence of mutations) resulting from a too low tumour cell content in the analysed samples, tumour cellularity was estimated by several methods: two independent and blind estimates by senior pathologists on an haematoxylin and eosin slide, and one bioinformatics method (Sequenza [25] tumours, targeted gene panels might have to evolve in order to also include such genes. As no additional therapeutic information was brought by WES in 8 of 10 samples, it is likely that techniques looking for other types of alterations-such as RNAseq or methylation profiling-may be more informative for such cases [37, 38] . However, we cannot exclude that the absence of interesting findings on aCGH, TGPS, and WES was simply related to the low tumour cellularity of some samples, as this latter directly affects the performance of these methods. Contamination of blood by tumour DNA, which may also happen in the case of advanced metastatic cancer, also decreases bioinformatics power when using blood as non-tumour reference sample.
Interestingly, the SCC of the tongue sample presented a probably damaging MLH1 missense mutation. Mismatch repair (MMR) deficiency [39] has been reported in up to 58% of head and neck SCC and associated with microsatellite instability (MSI) [40] . MMR deficiency and MSI have been correlated with a lower number of chromosomal abnormalities [41] , which might have explained some of the flat aCGH profiles. MSI status could not be evaluated in this series, but this suggests that search for MSI in selected histotypes might be of interest when presenting a flat aCGH profile.
Whether the earlier discovery of the five potentially actionable mutations in the two tumour samples would have changed the prognosis of corresponding patients is unknown. Only one out of these mutations-the FGFR3 Y373C missense SNV-had been previously described in the literature and associated with an activation of the corresponding protein [27] . FGFR3 mutations have been reported in, respectively, 60%-80% and 15%-20% of lowgrade and high-grade bladder carcinomas [42] . We can therefore reasonably hypothesize that this FGFR3-activating mutation was a potential oncogenic driver in this patient's disease, and that WES would have been of added value in the therapeutic decision process for this particular patient. The mutation, detected in a retroperitoneal lymph node, might also not have been present in the primary tumour. Altogether, considering tumour heterogeneity and the clonal nature of cancers [43, 44] , it is unsure whether this patient would have benefited from an FGFR-targeting therapy.
The number of molecular profiling analysis that can be performed on a unique tumour sample is necessarily finite. Tumour material availability, costs and accessibility constraints of highthroughput technologies restrain their routine use: it is therefore key to best optimize the sequence and combination of such techniques in order to get as much clinically relevant information as possible [11] . Our preliminary findings suggest that WES might provide limited added value when compared with the combination of appropriately selected TGPS and aCGH, at least for the tumour types described here. These observations, if replicated in larger cohorts, suggest that alternative techniques-including RNAseq, methylation profiling, or exome sequencing techniques allowing the detection of fusion genes-may be more informative in such context.
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